A Zantac, AH 19065, Azantac, Ranitidine hydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Zantac, AH 19065, Azantac, Ranitidine hydrochloride Certificate of Suitability (COS). The purpose of a Zantac, AH 19065, Azantac, Ranitidine hydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Zantac, AH 19065, Azantac, Ranitidine hydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Zantac, AH 19065, Azantac, Ranitidine hydrochloride to their clients by showing that a Zantac, AH 19065, Azantac, Ranitidine hydrochloride CEP has been issued for it. The manufacturer submits a Zantac, AH 19065, Azantac, Ranitidine hydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Zantac, AH 19065, Azantac, Ranitidine hydrochloride CEP holder for the record. Additionally, the data presented in the Zantac, AH 19065, Azantac, Ranitidine hydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Zantac, AH 19065, Azantac, Ranitidine hydrochloride DMF.
A Zantac, AH 19065, Azantac, Ranitidine hydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Zantac, AH 19065, Azantac, Ranitidine hydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Zantac, AH 19065, Azantac, Ranitidine hydrochloride suppliers with CEP (COS) on PharmaCompass.